Subcutaneous insulin infusion (CSII) therapy is a challenge for both patients and healthcare providers. The long-term CSII use is scarce. The aim of this study is to describe the impact of CSII therapy for 10 years of use at our center.
Methods:
This single-center retrospective study includes 162 type 1 diabetes patients using CSII for >3 years during October 2004 until October 2014. Data were collected through the electronic medical record system, cross-sectional analysis (telephone, e-mail, or social media), and CSII reports generated by Carelink Therapy Management Software (Medtronic, Northridge, CA).
Results:
Patients were analyzed in three age groups: 12–18, 19–24, and >25 years. All patients were treated with CSII for >3 years. Total daily dose of insulin was >0.9 U/(kg·day) in age group 12–18 years old, which was significantly higher than other two age groups (P < 0.05). Basal ratio was lower in younger age (<40%) and showed trend of increasing with age and longer diabetes duration (up to 44%). Younger patients used bolus wizard on regular basis (>75%), which was significantly higher than other age groups (P < 0.05). More than 50% of patients achieved glycated hemoglobin (HbA1c) <7.0% and >70% of patients achieved HbA1c <7.5%. HbA1c level significantly changed from baseline in all groups (P < 0.05).
Conclusion:
Our study shows improved glucose control in long-term CSII users. A reduction of HbA1c levels by −1.1% was maintained during the study period.
Get full access to this article
View all access options for this article.
References
1.
OnkamoP, VäänänenS, KarvonenM, et al.: Worldwide increase in incidence of Type I diabetes-the analysis of the data on published incidence trends. Diabetologia, 1999; 42:1395–1403.
2.
YouW-P, HennebergM: Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ Open Diabetes Res Care, 2016; 4:e000161.
3.
GaleEA: The rise of childhood type 1 diabetes in the 20th century. Diabetes, 2002; 51:3353–3361.
4.
International Diabetes Federation: IDF diabetes atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015.
5.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
6.
GoldenSH, BrownT, YehHC, et al.: Methods for insulin delivery and glucose monitoring: comparative effectiveness. Comp Effectiveness Rev, 2012; 57.
7.
YehHC, BrownTT, MaruthurN, et al.: Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med, 2012; 157:336–347.
8.
BlackmanSM, RaghinaruD, AdiS, et al.: Insulin pump use in young children in the T1D exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes, 2014; 15:564–572.
9.
VigerskyRA.: The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol, 2015; 9:320–330.
10.
GrunbergerG, AbelsethJM, BaileyTS, et al.: Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract, 2014; 20:463–489.
11.
CarlssonBM, AttvallS, ClementsM, et al.: Insulin pump long-term effects on glycemic control: an observational study at 10 diabetes clinics in Sweden. Diabetes Technol Ther, 2013; 15:302–307.
12.
MameliC, ScaramuzzaAE, HoJ, et al.: A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes. Acta Diabetol, 2014; 51:205–210.
13.
MatejkoB, CyganekK, KatraB, et al.: Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud, 2011; 8:254–258.
14.
PetrovskiG, DimitrovskiC, MilenkovicT: Clinical utility of continuous subcutaneous insulin infusion in patients with type 1 diabetes: a Macedonian experience. Diabetol Croat, 2006; 35:83–87.
PetrovskiG, DimitrovskiC, MilenkovicT: Insulin pump therapy with continuous glucose monitoring improves metabolic control in brittle type 1 diabetes. Prilozi, 2007; 28:129–135.
17.
PickupJC, SuttonAJ.: Severe hypoglycemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med, 2008; 25:765–774.
18.
MissoML, EgbertsKJ, PageM, et al.: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2010:CD005103.
19.
RodriguesAS, ReidHA, IsmailK, et al.: Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes mellitus: a clinical audit in a specialist service. Diabet Med, 2005; 22:842–849.
20.
RivelineJ-P, JolloisF-X, MessaoudiN, et al.: Insulin-pump use in everyday practice: data from an exhaustive regional registry in France. Diabetes Metab, 2008; 34:132–139.
21.
PetrovskiG, ZivkovicM: Impact of Facebook on glucose control in type 1 diabetes: a three-year cohort study. JMIR Diabetes, 2017; 2:e9
22.
PetrovskiG, ZivkovicM, StratrovaSS.: Social media and diabetes: can Facebook and Skype improve glucose control in patients with type 1 diabetes on pump therapy?. One-year experience Diabetes Care, 2015; 38:e51–e52.
23.
KlinkertC, BachranR, HeidtmannB, et al.: Age-specific characteristics of the basal insulin-rate for pediatric patients on CSII. Exp Clin Endocrinol Diabetes, 2008; 116:118–122.
24.
ColinoE, Martín-FríasM, YelmoR, et al.: Impact of insulin pump therapy on long-term glycemic control in a pediatric Spanish cohort. Diabetes Res Clin Pract, 2016; 113:69–76.
25.
AdolfssonP, ZieglerR, HanasR, et al.: Continuous subcutaneous insulin infusion: special needs for children. Pediatr Diabetes, 2017; 18:255–261.
26.
GiannoulakiP, GounitsiotiI, IliadisF, et al.: Bolus wizard use has a beneficial effect in glycemic control among people with diabetes type 1 on insulin pump therapy. Clin Nutr ESPEN, 2016; 13:e62–e63.
27.
AndersenAJ, OstenfeldA, PipperCB, et al.: Optimum bolus wizard settings in insulin pumps in children with type 1 diabetes. Diabet Med, 2016; 33:1360–1365.
28.
BonfantiR, LeporeG, BozzettoL, et al.: Italian Study Group on Diffusion of CSII in Italy. Survey on the use of insulin pumps in Italy: comparison between pediatric and adult age groups (IMITA study). Acta Diabetol, 2016; 53:403–412.
29.
CemerogluAP, ThomasJP, ZandeLT, et al.: Basal and bolus insulin requirements in children, adolescents, and young adults with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII): effects of age and puberty, Endocr Pract, 2013; 19:805–811.
30.
CohenND: Long-term metabolic effects of continuous subcutaneous insulin infusion therapy in type 1 diabetes. Diabetes Technol Ther, 2013; 15:544–549.
31.
QuirósC, GiménezM, RíosP, et al.: Long-term outcome of insulin pump therapy: reduction of hypoglycaemia and impact on glycaemic control. Diabet Med, 2016; 33:1422–1426.
32.
BrorssonAL, ViklundG, ÖrtqvistE, et al.: Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study. Pediatr Diabetes, 2015; 16:546–553.
33.
SamannA, MuhlhauserI, BenderR, et al.: Flexible insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. Diabetes Care, 2006; 29:2196–2199.
